Lyell
Oncology Therapeutics · Cell & Gene Therapy
3open roles
$240kmedian advertised pay
2backers · Foresite Capital, venBio Partners
50+team · employees, estimated range
Overview
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.
Funding and backers
Team
51-200
employees, estimated range
Hiring now
5
+3 posted in 30 days
Backers
2
Foresite Capital, venBio Partners
Momentum
39/100
hiring for its size, in the news
Last sign of life
1 mo ago
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
LynxBio is a clinical-stage biotechnology company combining physiologically relevant suspension cell co-culture assays, automated…
BrainChild Bio is a kids-first, clinical-stage biotechnology company harnessing the power of CAR-T cell technology for tumors in the…
Solstice Oncology is a clinical stage immuno-oncology company developing a therapeutic that meets cancer at its most vulnerable moment…
Optieum Biotechnologies is a biotechnology company that generates optimised scFvs to yield CAR-T cells with a strong anti-tumor effect. Its…
Bioarchitech develops multifunctional immunotherapies targeting cancer and virus-related diseases, including innovative viral and RNA-based…
East Ocyon Bio - Leading cell & gene therapy company in India developing CAR-NK, CRISPR, Gamma Delta T cells & mRNA therapies for cancer…
Jobs
$150k – $170k per year · Equity · In office · 10+ years exp · Bothell
PCR
Flow Cytometry
GMP
LIMS
MedTech
CAPA
Apply
$220k – $300k per year · Equity · In office · 20+ years exp · Master's Degree · Bothell
Cell Culture
GMP
MedTech
CAPA
Apply
$220k – $240k per year · Equity · In office · Master's Degree · United States
ICH Guidelines
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$240k
Typical range
$160k – $300k
Open positions
5
5
Jobs
Senior
60%
Staff
20%
Architect
20%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 3 | $300k | $160k – $300k |
| Staff | 1 | $170k | $170k |
| Architect | 1 | $240k | $240k |
Highest paying role
Director or Senior Director, Investor Relations and Corporate Communications
$300k
Normalized to USD per year
All salaries at Lyell
By role, level and city, against the market · 5 jobs with pay
Growth
Hiring Momentum
23/100
Hiring freeze
Open positions
5
0 opened / 0 closed in 30 days
Median time-to-fill
60 days
faster than 21% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Early Careers
40% ▲
Finance
20% ▼
Legal
10% ▲
Public Policy
10% ▼
Industrial Engineering
10% ▲
Biotech
10% ▼
Tech stack
Technologies named in job postings at Lyell over the last 12 months, by layer, with the share of postings for each.
Technologies in use
10
Postings analysed
6
Stack modernity
60/100AI adopter
Cloud & platforms
GCP
AI & ML
Claude
Sign in to see how your skills match this stack
Sign In
Full Lyell tech stack
10 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
venBio PartnersVia a fund
Foresite CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today
Read more
Report
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Technology transfer to LyFE Manufacturing Center completed following FDA review of improved manufacturing process and updated analytical methodsD...
Read more
Report
Lyell Immunopharma: Ronde-Cel Manufacturing Success Reaches 97% As Safety Data Supports Outpatient CAR-T
Lyell Immunopharma reported a 97% manufacturing success rate for its ronde-cel CAR-T therapy as safety data from more than 100 lymphoma patients supported the potential for treatment to be administered in an outpatient setting.
Read more
Report
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Detailed price information for Lyell Immunopharma Inc (LYEL-Q) from The Globe and Mail including charting and trades.
Read more
Report
Publishing exec, abuse survivor Jen Lyell remembered as Southern Baptist Convention meets
Jennifer Lyell uplifted others' stories in her Christian publishing career, and then her own story faced attacks. Her triumphs are being remembered.
Read more
Report
Report
Here's looking at shrew: How college students got first-ever photos of elusive California mammal
Three college students found a way to take photos of the Mt. Lyell shrew, which has never been photographed in the 100 years since the mammal was discovered.
Read more
Report
The framing of the shrew: California students photograph mammal never caught on film
Three young scientists set traps to capture and film species of special concern in move that can help conserve the shrew
Read more
Report
Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors
--Lyell Immunopharma, Inc.,, a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to initiate
Read more
Report
Lyell Immunopharma Announces cGMP Qualification of LyFE Manufacturing Center in Advance of Initiating Clinical Programs
--Lyell Immunopharma, Inc.,, a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that its LyFE Manufacturing Center in Bothell, Washington has been commissioned and qualified in compliance
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
4
Hiring now
3
Countries
1
Busiest office
South San Francisco
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
South San Francisco
United States
HQ
South San Francisco
2 open roles 3 posted in 90 days 10-50 est. staff $230k Avg Salary
hires for Finance, Legal
201 Haskins Way, Suite 101,, South San Francisco, CA 94080
Bothell
United States
Plant / site
Bothell
2 open roles 2 posted in 90 days 10-50 est. staff $235k Avg Salary
hires for Industrial Engineering, Early Careers
Seattle
United States
Regional office
South San Francisco
1 open roles 3 posted in 90 days 10-50 est. staff $160k Avg Salary
hires for Legal
West Hills
United States
Regional office
West Hills